Type 1 Diabetes Drugs Market|$ 2.83 billion growth expected during 2021-2025|17000+ Technavio Research Reports

NEW YORK, June 17, 2021 /PRNewswire/ — The type 1 diabetes drugs market is poised to grow by USD 2.83…

NEW YORK, June 17, 2021 /PRNewswire/ — The type 1 diabetes drugs market is poised to grow by USD 2.83 billion during 2021-2025, progressing at a CAGR of almost 6% during the forecast period.

Technavio’s in-depth market research reports include value chain analysis and validation techniques to help industry leaders improve their business.

Download FREE Sample Report

The report on the type 1 diabetes drugs market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.

The report offers an up-to-date analysis regarding the current global market scenario and the overall market environment. The market is driven by factors such as the growing prevalence of type 1 diabetes, the feasibility of early diagnosis of type 1 diabetes, and the expected launch of novel products.

The type 1 diabetes drug market analysis includes the product and geography landscape segments. This study identifies the expected launch of novel products as one of the prime reasons driving the type 1 diabetes drug market growth during the next few years.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

The type 1 diabetes drugs market covers the following areas:

Type 1 Diabetes Drugs Market Sizing

Type 1 Diabetes Drugs Market Forecast

Type 1 Diabetes Drugs Market Analysis

Companies Mentioned

  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Biocon Ltd.
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • MannKind Corp.
  • Novo Nordisk AS
  • Actiza Pharmaceutical Pvt. Ltd.
  • Sanofi SA
  • Viatris Inc.

Related Reports on Health Care Include:

Global Type 2 Diabetes Market– The type 2 diabetes market is segmented by drug class (insulin, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors, and others) and geography (North America, Europe, Asia, and ROW).

Download FREE Sample Report

Global Endocrinology Drugs Market– The endocrinology drugs market is segmented by therapy area (diabetes drugs, hGH, thyroid hormone disorders, and others) and geography (North America, Europe, Asia, and ROW).

Download FREE Sample Report

Key Topics Covered:

Executive Summary

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020- 2025

Five Forces Analysis

  • Five Forces Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Product

  • Market segments
  • Comparison by Product
  • Long-acting insulins – Market size and forecast 2020-2025
  • Rapid-acting insulins – Market size and forecast 2020-2025
  • Pre-mixed insulins – Market size and forecast 2020-2025
  • Non-insulin drugs – Market size and forecast 2020-2025
  • Market opportunity by Product

Customer Landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America – Market size and forecast 2020-2025
  • Europe – Market size and forecast 2020-2025
  • Asia – Market size and forecast 2020-2025
  • ROW – Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Actiza Pharmaceutical Pvt. Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Biocon Ltd.
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • MannKind Corp.
  • Novo Nordisk AS
  • Sanofi SA
  • Viatris Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: media@technavio.com

Website: www.technavio.com/

Newsroom: https://www.technavio.com/news/type-1-diabetes-drugsmarket

Report Page: https://www.technavio.com/report/type-1-diabetes-drugs-market-industry-analysis

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/type-1-diabetes-drugs-market-2-83-billion-growth-expected-during-2021-202517000-technavio-research-reports-301315171.html

SOURCE Technavio